Trial Profile
An Open-Label, Investigator Study to Evaluate the Short-term (4 Weeks) Effects of TOLCAPONE on Transthyretin Stability in Subjects With Leptomeningeal TTR Amyloidosis (ATTR) With and Without CNS Manifestations
Status:
Completed
Phase of Trial:
Phase 0
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Tolcapone (Primary)
- Indications Amyloidosis
- Focus Pharmacodynamics; Proof of concept
- 15 Sep 2020 According to a Corino Therapeutics media release, results from this study are presenting today at the XVII International Symposium on Amyloidosis.
- 15 Sep 2020 Results presented at a Corino Therapeutics media release.
- 12 Jun 2019 Status changed from active, no longer recruiting to completed.